Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC - CME - Guideline Central

CME

Title
Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC
Link
Description
You’ve taken the first step for you and your practice to achieve measurable changes that will ensure your infrastructure and processes are optimized to support guideline‑driven biomarker testing, individualized treatment, and coordination of care for patients with advanced NSCLC. Using this simple, systematic approach to quality improvement, intended for easy access and application in any practice setting, you will have the framework and tools you need to drive changes that positively impact care for your patients. Let’s get started!
Target Audience
This activity is intended for multidisciplinary providers treating patients with NSCLC in the community cancer setting including thoracic oncologists, thoracic surgeons, medical oncologists, molecular pathologists, pulmonologists, oncology pharmacists, clinical pharmacists, patient navigators, tissue navigators, and other members of the multidisciplinary team.
Learning Objectives
  • 1 - Assess
    • To assess possible areas of improvement, you will complete an assessment that asks to what extent you or your practice:
    • Assess all recommended biomarkers with multigene panel testing
    • Incorporate multidisciplinary workflows and processes for tissue collection, biomarker testing, and biomarker test interpretation
    • Implement protocols and procedures for biomarker testing using either in-house or outside labs
    • Integrate biomarker testing protocols and results with your electronic health record
    • Introduce workflows to reduce biomarker test turnaround times
    • Establishes multidisciplinary frameworks to interpret biomarker test results prior to initiation of systemic therapy
    • Implement guideline-directed therapy for patients with ERBB2-altered advanced/metastatic NSCLC Embeds treatment algorithms and protocols for advanced/metastatic NSCLC and actionable ERBB2 alterations within the electronic health record
    • You will receive a report card that summarizes your or your practice’s performance relative to areas assessed. This serves as your baseline and guides development of your personalized action items.
  • 2 - Implement in Practice
    • Working with our expert faculty, we created a Model for Improvement that outlines the aims of this program and its measures of success. We provide educational and practical interventions, but you can develop your own to meet your specific needs. Depending on your baseline assessment, interventions you can implement include:
    • Enhanced training
    • Communication strategies
    • Personalized action items to track based on the nuanced needs of your practice
    • Patient education
  • 3 - Re-assess
    • Once you’ve finished the interventions and have introduced the recommended process changes, it’s time to put them to the test!
    • Return to this digital QI portal after a minimum of 60 days
    • Re-assess your action plan to see what improvements were realized
    • Complete a personal reflection
    • Get your certificate
Estimated Duration
150 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Oncology, Pulmonology, Thoracic Surgery
Keywords
non-small-cell lung carcinoma (NSCLC)
Disclosures and Disclaimers
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity. Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Accredited Providers
  • University of Chicago Pritzker School of Medicine
Commercial Support
  • Boehringer Ingelheim Pharmaceuticals, Inc
Activity Expiration Date
April 1, 2028
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit2.5 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.